Vertex Acquires Crinetics for $10 Billion, Securing Palsofy and Atumelnant
Details have emerged regarding Vertex Pharmaceuticals (VRTX) acquiring Crinetics Pharmaceuticals (CRNT) for $10 billion in an exclusive deal. Crinetics, advised by J.P. Morgan, approached six potential acquirers, but only 'Party A' showed initial interest before withdrawing due to a $6 billion budget limit. With no competition, Vertex secured the deal by offering $85 per share, a 102% premium. This has raised concerns among some investors about the financial burden, as they perceive Vertex may have overpaid. However, Vertex's willingness to increase the price significantly, even without competition, suggests a strong belief in the unique value and future growth potential of the acquired assets.
The acquisition allows Vertex to expand beyond its core business of cystic fibrosis. Key assets include Palsofy (paltusotine), approved by the FDA and EMA in September 2025 for acromegaly, and Atumelnant, a treatment for congenital adrenal hyperplasia (CAH) currently in Phase 3 clinical trials. Both are once-daily oral medications, representing a significant improvement in patient convenience compared to existing injectable treatments. The company estimates the combined peak annual sales potential for these two products to exceed $5 billion.
The negotiations began at the J.P. Morgan Healthcare Conference in January 2026 and continued for several months. Vertex initially offered $78 per share in March, which was rejected. In April, the offer was increased to $83 per share, but Crinetics' board rejected it again, counter-offering $87 per share. Finally, after additional due diligence, Vertex submitted a final offer of $85 per share, which Crinetics accepted, leading to the final agreement on July 6.
Wall Street's reaction to the deal has been mixed. Paul Matteis of Stifel expressed concern that the $85 per share price is high, based on the most optimistic scenario for the pipeline. However, Brian Abrahams of RBC Capital Markets believes that Vertex has the capabilities to maximize the value of the assets and that the price is justified. With the deal expected to close in the third quarter of 2026, this acquisition is expected to set a significant precedent for future biotech M&A valuations.
This acquisition is significant because it allows Vertex (VRTX) to diversify its portfolio beyond its core business of cystic fibrosis and successfully enter the $1.5 billion global acromegaly market. Palsofy, the first once-daily oral medication approved for acromegaly, and Atumelnant, a Phase 3 treatment for congenital adrenal hyperplasia (CAH), are expected to replace Novartis' Sandostatin, the current standard injectable treatment, and generate up to $5 billion in annual sales. Although the $85 per share price (102% premium) raised concerns about overpayment, Vertex's ability to preemptively block other potential acquirers, such as Party A, and secure the assets is widely seen as a strategic move. From an industry and research perspective, this acquisition marks a turning point in the treatment paradigm for rare endocrine disorders, shifting from injectable to oral formulations, and is expected to have a significant impact on the design of future clinical trials. The commercial performance of the acquired assets and the Phase 3 data for Atumelnant after the deal closes in the third quarter will be key indicators for future biotech M&A valuations.
Source: BioPharma Dive (rss)
https://www.biopharmadive.com/news/vertex-crinetics-acquisition-deal-bidder-process/825952/